Search Results

Cytek Biosciences, Inc., a leading cell analysis solutions company, officially announced its Enhanced Small Particle Detection Option for its flagship Cytek Aurora™ and Cytek Northern Lights™ cell analysis systems.

Cytek® Biosciences, Inc., a leading cell analysis solutions company, reported financial results for the first quarter ended March 31, 2024.

Cytek Biosciences, Inc. today announced the company will be participating in the upcoming Goldman Sachs 45th Annual Global Healthcare Conference in Miami Beach, FL.

Cytek Biosciences, Inc., a leading cell analysis solutions company, announced that its Board of Directors has approved the repurchase of up to an aggregate of $50 million of its common stock, subject to compliance with applicable law.

Cytek Biosciences, Inc., a leading cell analysis solutions company, continues its commitment to advancing the cell analysis market by actively participating in key industry gatherings worldwide.

Today Cytek Biosciences, Inc. (Nasdaq: CTKB) announced that its 1-laser and 2-laser 6-color TBNK reagent cocktails have received China National Medical Products Administration (NMPA) approval for clinical diagnostic use on the Cytek® Northern Lights™-Clinical (NL-CLC™) cell analysis systems in hospitals, laboratories and clinics across China.